logo
Maroc Telecom's first quarter profit falls 5.9%

Maroc Telecom's first quarter profit falls 5.9%

Reuters25-04-2025

RABAT, April 25 (Reuters) - Morocco's largest telecom operator, Maroc Telecom (IAM.CS), opens new tab, reported a 5.9% drop in first quarter profit on Friday as falling revenue in Morocco offset growth at its African subsidiaries.
The company said profit attributable to shareholders totalled 1.43 billion dirhams ($154 million) for January-March and its consolidated revenue fell 2% from a year earlier to 8.8 billion dirhams.
The Reuters Tariff Watch newsletter is your daily guide to the latest global trade and tariff news. Sign up here.
Revenue in its main Moroccan market dropped 3.7% but rose 4.1% at its African subsidiaries, known as Moov Africa.
Maroc Telecom said its customer base grew 3.6% to 80 million, as it steps up investments in broadband and mobile payment services at African subsidiaries.
Maroc Telecom, which is also listed on Euronext Paris, is 53% controlled by the United Arab Emirates' Etisalat, with the Moroccan state owning 22%.
Besides Morocco, it operates subsidiaries in Benin, Burkina Faso, the Central African Republic, Chad, Gabon, Ivory Coast, Mali, Mauritania, Niger and Togo.
In March, Maroc Telecom said it will team up with competitor Inwi to roll out a 5G network in Morocco, with a joint investment of 4.4 billion dirhams over the next three years.
Under the deal, which is pending the approval of telecommunications regulator ANRT, the operators agreed to equally set up two joint ventures in charge of deploying 5G optic fibre and towers.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Britain facing race to avoid $1 billion in EU carbon tax costs
Britain facing race to avoid $1 billion in EU carbon tax costs

Reuters

time12 hours ago

  • Reuters

Britain facing race to avoid $1 billion in EU carbon tax costs

LONDON/BRUSSELS, June 2 (Reuters) - Britain will struggle to link its carbon market to the EU's in just seven months, to avoid UK companies facing the bloc's carbon border tariff and annual bills around 800 million pounds ($1.08 billion) from next year, market experts have said. Billed as part of a "reset" in relations after Britain's 2016 exit from the European Union, the two sides announced last month they will link their carbon emissions trading systems by the end of the year. But neither side has set a timeframe or detailed the work that must be done to make this happen before January, when Europe's carbon border tax kicks in. "It's probably still likely to take many years before linkage takes effect. The earliest is 2028, but it's more likely to be 2029 or even 2030," said Ben Lee, senior emissions analyst at Energy Aspects. The UK government said a key upside of linking to the EU's carbon market, or emissions trading system (ETS), is to avoid businesses being hit by the EU's carbon border tariff - which, starting next year, will impose fees on the CO2 emissions associated with imports of steel, cement and other goods. The UK government said avoiding these costs would save 800 million pound a year. But EU officials say to get exempted from the carbon border levy, Britain would need to have linked its carbon market to the EU's. "Full linkage will take several years given the complexity of the process, purely from a technical perspective," ClearBlue carbon market analyst Yan Qin said, adding that an "optimistic" scenario could see the link forged in 2027. A spokesperson for the British government said it will seek to agree a carbon market link as soon as is feasible. "We will not provide a running commentary on the progress of negotiations," they said. To make a link happen, the UK needs to adjust its national rules for issuing carbon trading permits, bring its emissions permit auctions in line with EU rules, and change its national cap on how much companies covered by the carbon market can emit. That's not all. The EU and UK schemes are also not yet aligned on how many free CO2 permits they give industries. And the EU carbon market has a special "reserve" which adds or removes permits from the market to help stabilise prices. Britain's scheme currently lacks a "reserve", though it has a cost containment mechanism that can act as a ceiling on prices, something the EU scheme does not have. "Resolving the question of a supply adjustment mechanism will likely be one of the technical calibrations that will need to be in place before the two systems can link," said Veyt senior analyst Ingvild Sorhus. Some businesses argue these issues are technically straightforward to resolve. "With the right political will, an ETS linking agreement between the EU and UK could be signed within 6 months, and operational by 2028," said Alistair McGirr, Head of Policy and Advocacy at British energy firm SSE. Industry group Energy UK said linkage negotiations could conclude within a year - but that Britain should seek an exemption from the EU carbon border levy until the link is sealed, in case talks drag into 2026. "It is a question not of major political roadblocks, but primarily of technical processes ... I'm not saying these are small problems, but they are simply not intractable problems," Energy UK Policy Director Adam Berman said, of the changes needed to allow the link. The UK plans to launch its own carbon border tariff a year later, in 2027. Brussels may be in less of a hurry. Britain's carbon market is less than a tenth of the size of the EU's, so a link would see British businesses gain access to a much more liquid market. The upside for the EU is less clear - although EU officials cite the bloc's aim to expand carbon pricing internationally, to ensure as many countries as possible put a price on greenhouse gas emissions. Companies also say the move would avoiding competitive distortions and reduce costs for both EU and UK consumers. Pascal Canfin, a French lawmaker in the European Parliament, said the upsides for Britain were more obvious than for the EU. "It's a political move," said Canfin, of the EU's motivation. "The UK was within [the EU] ETS before. I mean, it's not such a big deal to have it again." ($1 = 0.7387 pounds)

Amgen drug cuts small cell lung cancer death risk by 40%
Amgen drug cuts small cell lung cancer death risk by 40%

Reuters

time14 hours ago

  • Reuters

Amgen drug cuts small cell lung cancer death risk by 40%

June 2 (Reuters) - Amgen's (AMGN.O), opens new tab Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday. The Phase 3 trial of 509 patients showed that Imdelltra extended median overall survival by more than five months to 13.6 months, compared with 8.3 months for standard-of-care chemotherapy, the company said. The median length of time patients lived without their disease worsening, a measure known as progression-free survival, was 4.2 months for the Imdelltra group and 3.7 months for patients who received chemotherapy. Amgen said the trial results are intended to serve as confirmatory evidence to support last year's accelerated approval by the U.S. Food and Drug Administration of Imdelltra for patients with extensive stage small cell lung cancer whose disease worsened on or after platinum-based chemotherapy. The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago and published in The New England Journal of Medicine. Most lung cancer cases are non-small cell, while up to 15% are the more aggressive small cell variety targeted by Imdelltra, according to the American Cancer Society. The Amgen drug belongs to a class of treatments called bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body's immune system can kill the cancer. Amgen said 27% of trial patients treated with Imdelltra experienced serious side effects, including low white blood cell counts, compared with 62% of chemotherapy patients. Patients on Imdelltra reported improvements in cough and shortness of breath compared to the chemotherapy group. Cytokine release syndrome, a potentially dangerous condition that occurs when the body's immune system responds over aggressively to infection or immunotherapy drugs, was primarily low-grade and manageable, Amgen said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store